用多状态模型改进器官支持治疗试验的报告
该文阐述多状态模型如何为涉及器官支持治疗(OST)的随机临床试验提供直观分析框架,以更好描述和比较随访期间患者状态。通过重新分析两项近期OST随机对照试验,多状态框架能更清晰揭示干预对临床状态转换时机的影响,提供更丰富且更具临床相关性的治疗效应理解。
要点
- 多状态模型可直观分析OST试验中患者状态转换时机。
- 无OST天数作为复合终点可能掩盖临床差异。
- 多状态模型有助于解释和主要分析OST试验。
核心结论
- 多状态模型可显著提升器官支持治疗临床试验的解释和主要分析。
研究设计与样本
- 方法学文章,描述多状态模型核心原理、假设、优势和局限,并重新分析两项近期OST随机对照试验。
主要发现
- 多状态框架能更清晰揭示干预如何影响临床状态间转换的时机。
- 多状态模型提供更丰富且更具临床相关性的治疗效应理解。
临床怎么用
- 在涉及器官支持治疗的随机临床试验中,可考虑采用多状态模型描述和比较患者全程状态轨迹。
局限性
- 多状态模型依赖假设(如马尔可夫假设),且存在局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Managing critically ill patients in the ICU often involves organ support therapies (OSTs), such as mechanical ventilation, extracorporeal membrane oxygenation, renal replacement therapy, and various pharmacologic strategies. Clinical trials in this context pursue diverse goals, including improving survival, reducing OST use, facilitating weaning, or comparing timing of OST initiation, which leads to substantial heterogeneity in OST-related endpoints. One commonly used outcome, the number of OST-free days, has been criticized for its composite nature, which can obscure important clinical differences between patients with similar OST-free day values. Variability in how weaning success is defined, how intercurrent OST-free periods are handled, and how death is incorporated further complicates comparisons across trials. Objectives: To illustrate how multistate modeling can offer an intuitive framework for analyzing randomized clinical trials involving OSTs and how this approach allows researchers to better describe and compare patient conditions during the entire follow-up. Methods: We describe the core principles of multistate modeling, including its assumptions (e.g., the Markov assumption), advantages, and limitations. We then present two recent randomized controlled trials evaluating OSTs and identify the main statistical challenges encountered in their analysis. Measurements and Main Results: Using a multistate modeling approach, we reanalyzed both trials to characterize and compare patient trajectories over time. The multistate framework enabled clearer insight into how interventions impact the timing of transitions between clinical states, providing a richer and more clinically relevant understanding of treatment effects. Conclusions: Multistate modeling can substantially inform the interpretation and primary analysis of a clinical trial evaluating an OST.
引用
- Hajage D, Gaudry S, Combes A, et al. Improving the Reporting of Trials Evaluating Organ Support Therapies Using Multistate Modeling. Am J Respir Crit Care Med. 2025. PMID: 40315144. doi:10.1164/rccm.202408-1669OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。